Age-Related Macular Degeneration Market Overview
Age-Related Macular Degeneration Market reached US$ 15.43 billion in 2024 and is expected to reach US$ 26.58 billion by 2033, growing at a CAGR of 6.3% during the forecast period 2025-2033.
The global age-related macular degeneration (AMD) treatment market is primarily driven by rising prevalence. Moreover, due to advancements in diagnostics, the diagnosis rate has significantly increased, along with which, the treatment rate has seen positive growth.
Moreover, several companies are actively engaged in product development activities with novel mechanisms of action. These novel products have the potential to open a new therapeutic class for age-related macular degeneration (AMD) treatment. VEGF inhibitors are such products that have revolutionized the AMD treatment landscape.
North America has the highest market share due to the availability of advanced therapies and a greater portion of the revenue generated by market players.
Executive Summary
For more details on this report – Request for Sample
Age-Related Macular Degeneration Market Dynamics: Drivers & Restraints
The rising prevalence of age-related macular degeneration (AMD) is driving the market growth
Age-related macular degeneration is a condition that affects people as they age. As the global population ages, the incidence and overall prevalence of AMD are expected to rise. For instance, according to the World Health Organization (WHO), by 2030, one in every six persons in the world will be 60 or older. At this time, the proportion of the population aged 60 and up will rise from 1 billion in 2020 to 1.4 billion. By 2050, the global population aged 60 and up will double, and reach 2.1 billion. The number of people aged 80 and older is predicted to triple between 2020 and 2050, reaching 426 million.
According to a study by Wan Ling Wong et al, published in the Lancet Glob Health journal, the population with age-related macular degeneration (AMD) is expected to reach 288 million by 2040 from 196 million in 2020. This drastic increase in the prevalent population increases the demand for advanced therapies for AMD, which in turn improves the R&D activities, increases product launches, and market growth.
The high cost of treatment may restrain the market growth
At present, anti-VEGF drugs have established themselves as a standard of care for the AMD population. However, their high cost can pose a significant economic burden to the patients. For instance, one Eylea injection can cost up to US$ 2,000 per patient, and the Eylea HD injection can cost up to US$ 2,600 per patient. The patient needs these injections initially every 4 weeks, then 4-12 weekly thereafter, based on the condition and its severity. Patients with partial or no insurance coverage may not be able to afford the treatment, which can lead to lower adoption and market hindrance.
Age-Related Macular Degeneration Market Segment Analysis
The global age-related macular degeneration market is segmented based on type, treatment, patient type, and region.
The anti-VEGF drugs in the type segment accounted for 78.5% of the market share in 2024 in the global age-related macular degeneration market
Anti-vascular endothelial growth factor (VEGF) drugs have evolved as a promising therapeutic agent for the treatment of age-related macular degeneration, especially for wet age-related macular degeneration. These are intravitreal injections that slow down the disease progression by blocking the activity of VEGF and reducing the formation of abnormal blood vessels.
There are several approved anti-VEGF drugs currently revolutionizing the treatment of age-related macular degeneration. The majority of these drugs are monoclonal antibodies and include Ranibizumab, Brolucizumab, Faricimab, Bevacizumab, etc. They are effective in reducing the newly forming vasculature during the early stages of age-related macular degeneration, thereby delaying the progression of central vision loss. This direct and selective inhibition of neovascularization is the major reason behind their therapeutic efficacy and increased adoption rate.
Moreover, these drugs are expensive, and most of them are patent-protected. Manufacturers generate most of their revenue from sales of these products, which is another major contributing factor to their greater market share.
The novel therapies are also focused on this target mechanism, which reflects the segment’s highest growth rate in the forecast period. For instance, AbbVie and REGENXBIO Inc. are combinedly to develop a novel one-time gene therapy that targets the VEGF pathway for the treatment of wet age-related macular degeneration. On October 21, 2024, REGENXBIO Inc. announced positive results of phase 2 clinical trials. The data were presented to the American Academy of Ophthalmology (AAO), and the results suggest that ABBV-RGX-314 has the potential to revolutionize the treatment paradigm of wet age-related macular degeneration.
Age-Related Macular Degeneration Market Geographical Analysis
North America dominated the age-related macular degeneration market with the highest share of 48.4% in 2024
North America region is expected to hold the largest market share over the forecast period. North America is well known for its advanced healthcare industry. The higher expenditure on healthcare and rising awareness among people, the advancement of technologies for Age-Related Macular Degeneration (AMD) treatment, and rising prevalence are the major contributing factors for the region’s dominance.
For instance, in 2022, an epidemiology study published in the JAMA Ophthalmology Journal stated that the prevalent cases (above 40 years of age) of age-related macular degeneration in the U.S. were 18.34 million in 2019. For instance, according to the BrightFocus Foundation, nearly 20 million people in the U.S. are living with some form of age-related macular degeneration. This surge in patient population is expected to create a higher demand for advanced therapeutics. North America, especially the U.S., is at the forefront of developing these advanced therapeutics.
Moreover, the market players generate the majority of their product revenue from the North America region, especially from the U.S. For instance, in 2023, F. Hoffmann-La Roche Ltd generated approximately 4.4 billion USD for Vabysmo, an anti-VEGF therapy indicated in AMD. The company has generated approximately 75% of its revenue from the United States. Moreover, Regeneron Pharmaceuticals Inc. has generated approximately 62.5% of the 9.5 USD billion revenue of Eylea from the United States. This reflects the region’s dominating share in the global age-related macular degeneration (AMD) treatment market.
Age-Related Macular Degeneration Market Major Players
The major players in the age-related macular degeneration market are F. Hoffmann-La Roche Ltd., Regeneron Pharmaceuticals Inc., Novartis AG, Apellis Pharmaceuticals, Inc., Astellas Pharma Inc., Biocon, Samsung Bioepis, Bausch + Lomb, Alcon Inc., and Nature Made, among others.
Key Development
In May 2025, Bayer AG announced that China's National Medical Products Administration has approved Eylea 8 mg (aflibercept 8 mg) for treating neovascular age-related macular degeneration (nAMD) in China. The approval is based on positive results from the Phase III PULSAR trial, which showed comparable efficacy and safety with treatment intervals of 3 or 4 months. This marks a significant advancement in providing more durable treatment options for patients and caregivers.
Market Scope
Metrics | Details | |
CAGR | 6.3% | |
Market Size Available for Years | 2022-2033 | |
Estimation Forecast Period | 2025-2033 | |
Revenue Units | Value (US$ Mn) | |
Segments Covered | Type | Dry AMD, Wet AMD |
Treatment | Anti-VEGF Drugs, AREDS2 Supplements, Photodynamic Therapy, Others | |
Patient Type | Male, Female | |
Regions Covered | North America, Europe, Asia-Pacific, South America, and the Middle East & Africa | |
